U
FATE icon

UBS’s Fate Therapeutics FATE Stock Holding History

UBS’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-25,662
Closed -$250K – 10529
2014
Q1 		$250K Buy
25,662
+23,945
+1,395% +$185K ﹤0.01% 4961
2013
Q4 		$11K Buy
+1,717
New +$10.8K ﹤0.01% 8870

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

UBS's FATE Position: Q2 2014 in Review

UBS sold out of Fate Therapeutics (FATE) in Q2 2014, closing a stake of 25,662 shares — an estimated $250K sold.

UBS first reported a position in FATE in Q4 2013 and held it in 2 quarters. The position peaked at $250K in Q1 2014. 22 funds tracked by Wall St. Rank hold FATE as of Q2 2014.

  • UBS reported no remaining Fate Therapeutics position as of Q2 2014 after selling out during the quarter.
  • UBS sold 25,662 Fate Therapeutics shares in Q2 2014, an estimated $250K.
  • UBS first reported a position in Fate Therapeutics in Q4 2013 and held it in 2 quarters.
  • UBS's Fate Therapeutics position peaked at $250K in Q1 2014.
  • 22 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.